001). Conclusions: Antibiotherapy significantly reduces serum PSA only in EPS+ patients, which justifies limiting the use of prebiopsy anti biotics to EPS+ patients with a normal DRE and PSA level between 2.5 and 10 ng/ml, minimizing the major drawbacks of empirical antibiotics usage. Copyright (c) 2010 P5091 S. Karger AG, Basel”
“After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor function. Long-term
treatment with LD is, however, often complicated by the development of various types of motor response
oscillations over the day, as well as drug-induced dyskinesias. Motor fluctuations can be improved by the addition of drugs such as entacapone or monoamine oxidase inhibitors, which extend the half-life of levodopa Autophagy inhibitor or dopamine, respectively. However, dyskinesia control still represents a major challenge. As a result, many neurologists have become cautious when prescribing therapy with LD. This review summarizes the available evidence regarding the use of LD to treat PD and will also address the issue of LD delivery as a critical factor for the drug’s propensity to induce motor complications.”
“Gastrointestinal symptoms such as heartburn, indigestion (or dyspepsia), bloating, distension, constipation, abdominal pain, abdominal discomfort and diarrhoea are extremely common worldwide. For some, such symptoms can prove to be chronic and disabling.
The recent literature click here on irritable bowel syndrome and, in particular, work
emanating form this authors research group, was reviewed.
These functional symptoms commonly occur in aggregations, referred to as functional gastrointestinal disorders (FGIDs). Some of the FGIDs and, most notably irritable bowel syndrome (IBS), have achieved a degree of scientific and clinical credibility as coherent entities. Several lines of evidence ranging from gut motility to the microbiota are under investigation in attempts to explain IBS or its symptomatology.
Though biomarkers for IBS and other FGIDs have proven elusive, considerable progress has been made in understanding possible aetiological factors in IBS; progress which may well lead to better therapeutic strategies.”
“PURPOSE: To assess the accuracy of intraocular lens (IOL) power calculation using optical biometry in patients having combined phacovitrectomy for macular hole and macular pucker.
SETTING: Sunderland Eye Infirmary, North East England, United Kingdom.
METHODS: This single-surgeon retrospective case series review comprised eyes having combined narrow-gauge phacovitrectomy for macular hole or macular pucker. Intraocular lens power was calculated using the results of optical biometry and the Haigis formula.